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Abstract
Background: Membrane androgen receptors (mAR) are functionally expressed in a variety of tumor-cells including
the breast tumor-cell line MCF-7. They are specifically activated by testosterone albumin conjugates (TAC). The mAR
sensitive signaling includes activation of Ras-related C3 botulinum toxin substrate 1 (Rac1) and reorganization of the
actin filament network. Signaling of tumor-cells may further involve up-regulation of pore forming Ca2+ channel
protein Orai1, which accomplishes store operated Ca2+ entry (SOCE). This study explored the regulation of Orai1
abundance and SOCE by mAR.
Methods: Actin filaments were visualized utilizing confocal microscopy, Rac1 activity using GST-GBD assay, Orai1
transcript levels by RT-PCR and total protein abundance by western blotting, Orai1 abundance at the cell surface by
confocal microscopy and FACS-analysis, cytosolic Ca2+ activity ([Ca2+]i) utilizing Fura-2-fluorescence, and SOCE from
increase of [Ca2+]i following readdition of Ca
2+ after store depletion with thapsigargin (1 μM).
Results: TAC treatment of MCF-7 cells was followed by Rac1 activation, actin polymerization, transient increase of
Orai1transcript levels and protein abundance, and transient increase of SOCE. The transient increase of Orai1 protein
abundance was abrogated by Rac1 inhibitor NSC23766 (50 μM) and by prevention of actin reorganization with
cytochalasin B (1 μM).
Conclusions: mAR sensitive Rac1 activation and actin reorganization contribute to the regulation of Orai1 protein
abundance and SOCE.
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Background
Membrane androgen receptors (mARs) are functionally
expressed in various tumor cells including prostate [1–6],
breast [6–9] and colon cancer cells [10, 11] as well as gli-
omas [12]. The mARs are specifically activated by mem-
brane impermeable testosterone albumin conjugates
(TAC) [5, 13, 14]. Signaling mediating the cellular effects
of mAR’s include the early FAK/PI3K/SGK1/Rac1/Cdc42
and Rho/ROCK/LimK cascades and late GSK/beta-ca-
tenin pathway leading to profound actin reorganization
[5, 7, 9, 14–18]. Activation of mARs eventually leads to
modification of tumor cell proliferation, migration and
apoptosis [5, 6, 13, 14, 19].
Cell proliferation, migration and cell death are regu-
lated by alterations of cytosolic Ca2+ activity [20–23]. A
powerful regulator of cytosolic Ca2+ concentration is the
pore forming Ca2+ channel subunit Orai1 accomplishing
store operated Ca2+ entry (SOCE) [24–30]. In a recent
study, activation of mAR by dehydrotestosterone (DHT)
in prostate cancer cells was reported to induce rapid Ca2+
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influx via Orai that was important for rapid androgen
effects [31].
The present study explored, whether mAR activation
is followed by alterations of Orai1 protein abundance
and function in MCF-7 breast tumor cells and addressed
the role of actin reorganization and actin signaling to
this effect. To this end, MCF-7 cells were exposed to
TAC and Orai1 protein abundance at the cell surface
was determined by confocal microscopy and flow cytom-
etry as well as intracellular Ca2+ release and SOCE were
quantified utilizing Fura-2 fluorescence.
Results and discussion
The present study explored the effect of membrane an-
drogen receptor (mAR) activation on Ca2+ signaling in
MCF-7 breast cancer cells. To this end, MCF- cells were
treated with testosterone-albumin conjugates (TAC,
100 nM), which selectively activate mAR without activat-
ing intracellular androgen receptors (iAR). In a first step,
confocal microscopy was employed to visualize the effect
of TAC on the Orai1 protein abundance at the MCF-7
cell membrane surface. As illustrated in Fig. 1, mAR ac-
tivation was followed by a rapid increase of Orai1 pro-
tein abundance at the surface of MCF-7 cells.
Quantitative analysis revealed that mAR activation sig-
nificantly increased Orai1 abundance within 15 min, an
effect that was persistent for at least 120 min (Fig. 1b).
Orai1 was colocalized with Na+/K+ ATPase (Fig. 1c). In
contrast to Orai1 abundance, the Na+/K+ ATPase pro-
tein abundance was similar without mAR activation
(24.5 ± 1.1 a.u., n = 5) and 1 h (24.7 ± 2.2 a.u., n = 5) or 2
h (25.0 ± 1.9 a.u., n = 5) following mAR activation. The
increased Orai1 abundance in the cell membrane was
paralleled by an increase of Orai1 transcript levels
(Fig. 2a) and protein abundance (Fig. 2b).
As shown in Fig. 3, the effect of mAR activation on
Orai1 abundance was paralleled by a profound
reorganization of the actin cytoskeleton of MCF-7 cells.
According to Fig. 4, the treatment of MCF-7 cells with
TAC was followed by rapid and transient activation of
the Rac1 protein, an effect abrogated by the specific
Rac1 inhibitor NSC23766 (50 μM).
As illustrated in Fig. 5, the effect of mAR activation on
Orai1 abundance of MCF-7 cells was prevented by pres-
ence of each, cytochalasin B (1 μM) and Rac inhibitor
NSC23766 (50 μM) (TAC+ Rac inhibitor), suggesting
that actin reorganization may represent an important
Orai1-regulator.
Fig. 1 Effect of mAR activation on Orai1 protein abundance at the surface of MCF-7 cells. a Original confocal microscopy of non-permeabilized
MCF7 cells treated for 15–120 min with TAC-BSA (100 nM) and stained with anti-Orai1 antibody (green) and DRAQ-5 (blue) for nuclei. b Arithmetic
means ± SEM (n = 6) of Orai1 protein abundance in non-permeabilized MCF-7 cells without (white bar) and with (black bars) a 15 min to 120
min treatment with testosterone-albumin-conjugates (TAC, 100 nM). ***(p < 0.001) indicates statistically significant difference from absence of
TAC. c Original confocal microscopy demonstrating colocalization of Orai1 (green) and Na+/K+ ATPase (red) in MCF7 cells. DRAQ-5 (blue)
indicates nuclei
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Flow cytometry was employed to further quantify the
alterations of Orai1 protein abundance at the MCF-7
cell surface. The TAC treatment of MCF-7 cells was
followed by a transient increase of the Orai1 protein
abundance in MCF-7 cells (Fig. 6). The effect of TAC on
Orai1 protein abundance at the MCF-7 cell surface was
not significantly modified by the intracellular androgen
receptor blocker flutamide (1 μM), but was virtually ab-
rogated in the presence of cytochalasin B (1 μM) or the
presence of Rac inhibitor NSC23766 (50 μM). Similar
results were obtained in non-permeabilized cells (Fig. 7).
Fura-2 fluorescence was employed to quantify alter-
ations of cytosolic Ca2+ activity ([Ca2+]i). The store op-
erated Ca2+ entry (SOCE) was apparent from increase
Fig. 2 Effect of mAR activation on Orai1 transcript levels and total protein abundance. a Arithmetic means ± SEM (n = 6) of Orai 1 transcript levels as
determined by RT-PCR in MCF-7 cells without (white bar) and with (black bars) a 60 min treatment with testosterone-albumin-conjugates (TAC, 100
nM). *(p < 0.05) indicates statistically significant difference from absence of TAC. b Original Western blot and arithmetic means ± SEM (n = 3) of protein
abundance in MCF-7 cells without (white bar) and with (black bars) a 60 min and 120 min treatment with testosterone-albumin-conjugates (TAC, 100
nM). *(p < 0.05) indicates statistically significant difference from absence of TAC
Fig. 3 Modulation of dynamic actin polymerization by mAR activation of MCF-7 cells. a Original confocal images of rhodamine-phalloidin binding
to F-actin (red) and DRAQ-5 for nuclei (blue) in MCF-7 cells without (control) and with a prior 15–120 min treatment with testosterone-albumin-
conjugates (TAC, 100 nM). Arrows point to formation of actin stress fibers. b Arithmetic means ± SEM (n = 6) of actin fluorescence in MCF-7 cells
without (white bar) and with (black bars) a 15 min to 120 min treatment with testosterone-albumin-conjugates (TAC, 100 nM). *(p < 0.05) and
***(p < 0.001) indicate statistically significant difference from absence of TAC
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of [Ca2+]i following readdition of extracellular Ca
2+
after store depletion with the sarcoendoplasmatic
reticulum Ca2+ ATPase (SERCA) inhibitor thapsigargin
(1 μM). As illustrated in Fig. 8, TAC treatment had lit-
tle effect on thapsigargin-induced intracellular Ca2+ re-
lease but was followed by a marked transient increase
of both, slope and peak, of SOCE in MCF-7 cells.
SOCE was virtually disrupted by the Orai1 inhibitor 2-
APB (50 μM).
The present study reveals that activation of membrane
androgen receptors (mARs) by testosterone albumin
conjugates (TAC) triggers a strong transient increase of
Orai1 protein abundance in the MCF-7 breast cancer
cell surface. This effect was not dependent on the intra-
cellular androgen receptor, as shown by control experi-
ments in the presence of the anti-androgen drug
flutamide. It was paralleled by and presumably
accounted for a profound increase of store operated Ca2
+ entry. The effects required activation of Rac1 GTPase
and reorganization of the actin cytoskeleton. Accord-
ingly, the up-regulation of Orai1 was virtually abrogated
by Rac1 inhibitor NSC23766 and by disruption of the
actin filament network with cytochalasin B.
Orai1 contributes to the regulation of cell proliferation
[32–37]. Stimulation of SOCE triggers Ca2+ oscillations
[38, 39], which influence a wide variety of cellular func-
tions [40–44]. Notably, the Ca2+ oscillations trigger
depolymerization of actin filaments [40, 45]. As
depolymerization of the actin filaments disrupts the ef-
fect of mARs on Orai1 protein abundance, it is tempting
to speculate that it is the Ca2+-induced depolymerization
of the actin filaments, which leads to the transient na-
ture of the TAC effect. At least in some cells, Ca2+ oscil-
lations and actin depolymerization are required for the
stimulation of cell proliferation [40].
Actin reorganization following mARs activation, regu-
lated by various actin signaling pathways [46] modifies
several cellular functions including stimulation of apop-
tosis [10, 11, 14, 47] and migration [7, 11, 16]. The
mAR-induced apoptotic response in breast cancer cells
is disrupted by the actin cytoskeleton inhibitor cytocha-
lasin B that blocks the observed actin reorganization [9].
Similar to the effect of mAR activation on Orai1 abun-
dance, the effect of mAR on apoptosis requires actin
polymerization. Thus, actin reorganization is a pivotal
response of cells to activation of mARs, as well as to ef-
fects on apoptosis, cell death and aging [13, 48–52]. The
mechanism by which Orai 1 abundance may be regu-
lated by the Rac1 governed actin reorganization remains
to be elucidated. Regulation of ORAI1 gene transcription
may well involve early actin redistribution, as this was
previously reported for the transcription of various genes
encoding specific regulatory effectors [53–55]. Moreover,
the cytoskeleton may impact on trafficking of expressed
Orai1 protein to the cell membrane [56–59]. However,
additional experimental efforts are required to fully
understand the complex signaling of mAR induced cel-
lular functions and death [46].
Conclusions
In conclusion, transient up-regulation of Orai1 protein
abundance and transient increase of store operated Ca2+
entry contribute to the signaling of the membrane an-
drogen receptors. Actin reorganization, regulated by
mAR-induced early Rac1 GTPase activation is involved
in the regulation of Orai1 protein abundance and SOCE.




MCF-7 mammary adenocarcinoma cells, provided from
ATCC were cultured in DMEM high glucose medium
(Gibco) containing 10 % FBS and 1 % penicillin/strepto-
mycin in a humidified atmosphere of 5 % CO2. Based on
previous titration experiments [2, 7, 10] for mAR stimu-
lation, we have used throughout this study the non-
Fig. 4 Effect of mAR activation on abundance of activated Rac1
protein in MCF-7 cells. a Affinity precipitation with GST (glutatione
S-transferase) -PBD (p21 binding domain) revealing by immunoblotting
(IB) the protein abundance of activated (upper lane) and total (lower
lane) Rac1 prior to (control) and 15–120 min following treatment
with testosterone-albumin-conjugates (TAC, 100 nM) and TAC +
Rac1 inhibitor NSC23766 (50 μM). b Arithmetic means ± SEM (n =
4) of the relative fold increases of activated over total Rac1 protein
abundance prior to (taken as 1) and 15–120 min following treatment
with testosterone-albumin-conjugates (TAC, 100 nM) and TAC + Rac1
inhibitor NSC23766 (50 μM). **(p < 0.01) indicates statistically significant
difference from absence of TAC
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permeable androgen derivative testosterone-BSA (TAC,
Sigma-Aldrich) in a concentration of 100 nM. In some
experiments, the anti-androgen drug flutamide (1μM,
Sigma), the Rac1 inhibitor NSC23766 (50 μM) or the
actin cytoskeleton-disrupting agent cytochalasin B (1μM,
Sigma-Aldrich) were used as indicated.
Confocal laser scanning microscopy
For actin, Orai1 and Na+K+ATPase staining, 7 × 104
MCF-7 cells were cultured for 24 h on glass cover slips
and treated or not with TAC-BSA (100 nM, Sigma), cyto-
chalasin B (1μM, AppliChem) and Rac1 inhibitor
NSC23766 (50 μM) for different time periods as indicated
in the figure legends. After washing twice with PBS, cells
were fixed with 4 % PFA for 15 min and then blocked with
3 % BSA in PBS for 1 h at room temperature. Then, the
cells were exposed to anti-Orai1 primary antibody (1:200,
Abcam #ab 59330) or/and anti- Na+K+ATPase (Sigma,
USA) at 4 °C overnight. The cells were rinsed three times
with PBS and incubated with secondary antibody for
Orai1 CF™ 488A-labeled anti–rabbit (1:250, Sigma, USA)
and for Na+K+ATPase CF™ 555-labeled anti-mouse anti-
body (1:250, Sigma, USA) for 1 h at room temperature.
Additional cells were incubated with rhodamine-
phalloidin (1:200, Life Technologies, USA) for F-actin and
with DRAQ-5 dye (1:3000, Biostatus, Leicestershire, UK)
for nuclei staining for 30 min in the dark. All slides were
mounted with ProLong Gold antifade reagent (Life Tech-
nologies, USA). Images were subsequently taken on a
Zeiss LSM 5 EXCITER confocal laser scanning micro-
scope (Carl Zeiss, Germany) with a water immersion
Plan-Neofluar 63/1.3 NA DIC [60, 61]. The mean fluores-
cence from six related cells of each picture was quantified
by ZEN software (Carl Zeiss, Germany).
Fig. 5 Effect of mAR activation on actin cytoskeleton and membrane Orai1 abundance of MCF-7 cells. a Original confocal microscopy of actin
filaments (red) and Orai1 (green) in non-permeabilized MCF-7 cells without (control) and with a prior 60 min treatment with testosterone-albumin-
conjugates (TAC, 100 nM) alone (TAC) or together with cytochalasin B (1 μM) (TAC + cytochalasin B), or with Rac inhibitor NSC23766 (50 μM) (TAC+ Rac
inhibitor). b, c Arithmetic means ± SEM of (b) Orai1 abundance (n = 6) and of (c) actin fluorescence (n= 6) in MCF-7 cells without (white bar) and with
(black bars) a 60 min treatment with testosterone-albumin-conjugates (TAC, 100 nM). ***(p < 0.001) indicates statistically significant difference from
absence of TAC, ###(p < 0.001) indicates statistically significant difference from presence of TAC without presence of inhibitors
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Quantitative RT-PCR
To determine Orai1 gene expression, MCF7 cells were
washed twice with PBS, and lysed with 1ml TriFast
Reagent (Peqlab, Erlangen, Germany). The RNA was
isolated according to the manufacturer’s protocol. 2.5
μg of the RNA were transcribed to cDNA using the
GoScript™ Reverse Transcription System (Promega
Corporation, Madison, USA) and oligo-dT primers.
Quantitative real-time PCR was performed on the
CFX96 cycler (Bio-Rad) in a total volume of 20 μl
using 2 μl of cDNA, and 2x GoTaq® qPCR Master Mix
(Promega Corporation, Madison, USA). Cycling condi-
tions were initial denaturation at 95 °C for 5 min,
followed by 40 cycles of 95 °C for 15 s, 59 °C for 30 s
and 72 °C for 30 s.
The following primers were used (5′- > 3′orientation):
ORAI1 forward primer: AGCCTCAACGAGCATCC
CAT
ORAI1 forward reverse primer: CTGATCATGAGCG
CAAACAGG
GAPDH forward primer: TGAGTACGTCGTG
GAGTCCACTG
GAPDH reverse primer: CACCACCAACTGCTTAGC
ACC
Relative quantification of the gene expression was
achieved using the ΔΔCt method and GAPDH as house-
keeping gene.
Western blotting
Cells were incubated with with TAC-BSA (100 nM, Sigma)
for the indicated time periods, washed twice with ice-cold
PBS and suspended in ice-cold lysis buffer (50 mM Tris/
Fig. 6 Total Orai1 abundance in MCF-7 cells following mAR activation in absence and presence of cytochalasin B and Rac1 inhibitor NSC23766.
a-e Original histogram of anti-Orai1 fluorescence in permeabilized MCF-7 cells without (a) and with (b-e) a 60 min treatment with testosterone-
albumin-conjugates (TAC, 100 nM) in the absence (b) and presence of flutamide (c), cytochalasin B (d) and Rac inhibitor (e). f Arithmetic means ±
SEM (n = 6) of the Orai 1 protein abundance in permeabilized MCF-7 cells without (white bar) and with a 15 min to 24 h treatment with
testosterone-albumin-conjugates (TAC, 100 nM) in the absence (black bars) and presence of flutamide (1 μM) (dark grey bars) cytochalasin B
(1 μM) (middle grey bars), or Rac inhibitor NSC23766 (50 μM) (light grey bars). ***(p < 0.001) indicates statistically significant difference from
absence of TAC, ###(p < 0.001) indicates statistically significant difference from presence of TAC without presence of inhibitors
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HCl, 1 % TritonX-100 pH 7.4, 1 % sodium deoxycholate,
0.1 % SDS, 0.15 % NaCl, 1 mM EDTA, 1 mM sodium
orthovanadate) containing a protease inhibitor cocktail
(Sigma). The protein concentration was determined using
the Bradford assay (BioRad). 40 μg of total proteins were
boiled with Roti-Load sample buffer (Carl Roth, Germany)
for 5 min at 95 °C and separated in 10 % SDS-PAGE. Pro-
teins were transferred to a PVDF-membrane (Thermo
Fisher Scientific, USA) and blocked for 1 h at room
temperature with 5 % BSA (Carl Roth, Germany) in TBST.
For immunostaining membranes were incubated over-
night at 4 °C with anti-Orai1 (1:1000, Cell Signaling) and
GAPDH (1:3000, Cell Signaling, USA) antibodies. To de-
tect the specific proteins membranes were incubated for
1h at RT with a 1:2000 dilution of anti-rabbit IgG
conjugated to horseradish peroxidase (Cell Signaling,
USA). After washing, bands were visualized using the ECL
western blotting detection reagent (GE Healthcare, USA)
and quantified by Quantity One Software (ChemiDoc
XRS, Bio-Rad, USA).
Rac1 activity
Rac1 activity was determined utilizing affinity precipita-
tion with GST-PBD as described previously [62]. In
brief, cells, treated or not with TAC (100 nM) in the
presence or absence of the specific Rac1 inhibitor
NSC23766 (50 μM) were lysed in Mg2+ lysis buffer
(Upstate Biotechnology, Inc.) and incubated with 200 μl of
binding buffer composed of (all in mM) 25 Tris–HCl (pH
7.5), 1 DTT, 30 MgCl2, 40 NaCl, and with added 0.5 %
Fig. 7 Cell membrane Orai1 abundance in MCF-7 cells following mAR activation in absence and presence of cytochalasin B and Rac1 inhibitor
NSC23766. a-d Original histogram of anti-Orai1 fluorescence in non-permeabilized MCF-7 cells without (a) and with (b-d) a 60 min treatment with
testosterone-albumin-conjugates (TAC, 100 nM) in the absence (b) and presence of cytochalasin B (c) and Rac inhibitor (d). e Arithmetic means ±
SEM (n = 6) of the Orai 1 protein abundance in non-permeabilized MCF-7 cells without (white bar) and with a 60 min treatment with testosterone-
albumin-conjugates (TAC, 100 nM) in the absence (black bar) and presence of cytochalasin B (1 μM) (middle grey bars), or Rac inhibitor NSC23766
(50 μM) (light grey bars). ***(p < 0.001) indicates statistically significant difference from absence of TAC, ##(p < 0.01) indicates statistically significant
difference from presence of TAC without presence of inhibitors
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Nonidet P-40, and 5 μl glutathione-Sepharose 4B beads at
4 °C. The bead pellet was then washed 3 times with a buf-
fer composed of (in mM) 25 Tris–HCl (pH 7.5), 1 DTT,
30 MgCl2, 40 NaCl, with or without added 1 % Nonidet P-
40. The bead pellet was finally suspended in 20 μl of
Laemmli sample buffer. Proteins were separated by 11 %
SDS-PAGE, transferred onto nitro-cellulose membrane,
and immunoblotted with anti-Rac1 antibody (1:1000, Cell
Signaling, USA).
FACS analysis of Orai1 surface and total protein
abundance
Orai1 surface expression was analyzed by flow cytome-
try. To this end, the cells were detached, washed three
times with phosphate-buffered saline (PBS) and fixed
with 4 % paraformaldehyde for 15 min on ice without
(for surface protein) or with (for total protein)
permeabilization with 0.1 % Triton X-100 for 5 min.
Then the cells were incubated for 60 min (37 °C) with
anti-Orai1 primary antibody (1:200, Abcam), washed
once in PBS, and stained in 1:250 diluted CF™ 488A-
labeled anti–rabbit secondary antibody (Sigma, USA) for
30 min (37 °C). Samples were immediately analyzed on a
FACS Calibur flow cytometer (BD Biosciences).
Ca2+ measurements
Fura-2 fluorescence was utilized to determine intracellu-
lar Ca2+ activity [63]. Cells were loaded with Fura-2/AM
(2 μM, Invitrogen, Goettingen, Germany) for 20 min at
37 °C. Cells were excited alternatively at 340 nm and
380 nm through an objective (Fluor 40×/1.30 oil) built
in an inverted phase-contrast microscope (Axiovert 100,
Zeiss, Oberkochen, Germany). Emitted fluorescence in-
tensity was recorded at 505 nm. Data were acquired
using specialized computer software (Metafluor, Univer-
sal Imaging, Downingtown, USA). Cytosolic Ca2+ activity
was estimated from the 340 nm/380 nm ratio. SOCE
was determined by extracellular Ca2+ removal and
subsequent Ca2+ readdition in the presence of thap-
sigargin (1 μM, Invitrogen) [64]. For quantification
of Ca2+ entry, the slope (delta ratio/s) and peak
(delta ratio) of Ca2+-entry were calculated.
Experiments were performed with Ringer solution
containing (in mM): 125 NaCl, 5 KCl, 1.2 MgSO4, 2
Fig. 8 Effect of mAR activation on intracellular Ca2+ release and store operated Ca2+ entry (SOCE) in MCF-7 cells. a Representative tracings of
fura-2 fluorescence-ratio in fluorescence spectrometry before, during and after Ca2+ depletion with subsequent addition of thapsigargin (1 μM) in
MCF-7 cells without (control, open squares) and with (grey and black squares) treatment with testosterone-albumin-conjugates (TAC, 100 nM) for
15–120 min in the absence and presence of the Orai-1 inhibitor 2-APB (50 μM). b, c Arithmetic means (± SEM, n = 3–5, each experiment 10–30
cells) of slope (b) and peak (c) increase of fura-2-fluorescence-ratio following re-addition of extracellular Ca2+ in MCF-7 cells without (control,
white bars) and with (grey and black bars) treatment with TAC (100 nM) for 15–120 min in the absence and presence of the Orai-1 inhibitor
2-APB (50 μM). ***(p < 0.001) indicates statistically significant difference from absence of TAC, ###(p < 0.001) indicates statistically significant
difference from 60 min presence of TAC without presence of 2-APB (ANOVA)
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CaCl2, 2 Na2HPO4, 32 HEPES, 5 glucose, pH 7.4. To
reach nominally Ca2+-free conditions, experiments were
performed using Ca2+-free Ringer solution containing
(in mM): 125 NaCl, 5 KCl, 1.2 MgSO4, 2 Na2HPO4, 32
HEPES, 0.5 EGTA, 5 glucose, pH 7.4.
Statistical analysis
Data are provided as means ± SEM, n represents the
number of independent experiments. Data were tested
for significance using unpaired student’s t-test or
ANOVA as appropriate. Differences were considered
statistically significant when p-values were < 0.05. Statis-
tical analysis was performed with GraphPad InStat ver-
sion 3.00 for Windows 95, GraphPad Software, San
Diego California USA, www.graphpad.com.
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